科美诊断(688468.SH)2025年度归母净利润4440.76万元 同比下降65.05%

Core Viewpoint - Company reported a significant decline in both revenue and net profit for the fiscal year 2025, indicating challenges in the external diagnostic industry and internal strategic investments [1] Financial Performance - The company achieved operating revenue of 332.68 million yuan, a decrease of 23.75% compared to the same period last year [1] - The net profit attributable to the parent company was 44.41 million yuan, down 65.05% year-on-year [1] Factors Affecting Performance - The primary reason for the decline in operating performance was the deep implementation of centralized procurement in the in vitro diagnostic industry, which pressured product prices and led to a decrease in main business revenue [1] - The company maintained high research and development investment to enhance core competitiveness, indicating a strategic focus on product innovation despite financial challenges [1] - There was a reduction in government subsidies and other non-recurring profit and loss items compared to the previous year, further impacting overall financial results [1]